Induced pluripotent stem cell modeling of malaria by Nah, Shirley
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2014
Induced pluripotent stem cell
modeling of malaria
https://hdl.handle.net/2144/15082
Boston University
	   	   	  
BOSTON UNIVERSITY 
 
SCHOOL OF MEDICINE 
 
 
 
 
 
Thesis 
 
 
 
 
 
INDUCED PLURIPOTENT STEM CELL DISEASE MODELING OF MALARIA 
  
  
  
  
by 
  
  
  
  
SHIRLEY K NAH 
  
B.A., Wellesley College, 2010 
  
  
  
  
  
  
  
Submitted in partial fulfillment of the 
  
requirements for the degree of 
  
Master of Arts 
  
2014  
	   	   	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2014 by 
 SHIRLEY K NAH 
 All rights reserved  
	   	   	  
Approved by 
 
 
 
 
First Reader   
 George J Murphy, Ph.D. 
 Assistant Professor of Medicine 
 
 
Second Reader   
 Gwynneth D Offner, Ph.D. 
 Director M.A. in Medical Science Program 
 Associate Professor of Medicine 
 
 
 
 
	  	   iv 
DEDICATION 
  
This thesis is dedicated to my family. Thank you for supporting me and believing 
in me when I didn’t believe in myself. We did it! 
I also dedicate this thesis to the entire Murphy Lab, which has served as a second 
family to me. “The kids”: my brother Brenden Smith, whose jokes and brilliance 
consistently left me in gleeful awe, my cat Amy Leung, whose ornery post-doctoral 
attitude taught me the value of feigned indifference (and honest affection), and my sister 
Sarah Rozelle, who-- like a true older sibling-- paved the way for me to complete this 
process by fighting many of my battles and succeeding in ways no one else in the 
Murphy lab has, and finally, my younger siblings, James Murithi and Whitney Reid 
(Fink), who have surpassed me in so many ways that it seems unfitting that I should have 
ever had a hand in shaping their scientific careers. 
  
  
	  	   v 
ACKNOWLEDGMENTS 
 
I would like to thank my first reader Dr. George Murphy without whom this thesis 
could not have been written. His unfailing support, constant guidance, and knowledge 
have supported me throughout this process. He has challenged me to not only be a better 
researcher but also a wiser person. I cannot thank him enough. I would also like to thank 
my second reader Dr. Gwynneth Offner for all of her feedback and insight. Without her 
wisdom and constant accessibility, I would have remained lost and left behind in what 
has been an incredible year. 
 
 
  
	  	   vi 
INDUCED PLURIPOTENT STEM CELL MODELING OF MALARIA 
SHIRLEY K NAH 
  
ABSTRACT 
            Malaria is one of the oldest parasitic diseases known to man, and the disease has 
played a role in shaping civilizations and the success of human populations over many 
centuries. While the malaria is well studied, it still remains a worldwide killer—claiming 
about 600,000 lives annually with children under the age of five representing a 
disproportionate population of those lethally infected. Malaria is caused by the protozoan 
parasite Plasmodium, which is introduced to the human body through the bite of a 
female Anopheles mosquito.  The most lethal form of the disease is carried by the 
parasite Plasmodium falciparum, while the most widespread form of malaria is caused 
by Plasmodium vivax, the latter of which has a specific mode of entry and life cycle that 
makes it difficult to eradicate. The entry of P. vivax into human reticulocytes is based on 
the presence of the Duffy antigen chemokine receptor (DARC), which is uniquely absent 
in two-thirds of the Black population and populations of immediate African descent 
making it rare in the African region while endemic in Western and Asian countries. 
Inability to culture the parasite P. vivax in vitro and exhaustible tissue samples makes an 
accurate model of P. vivax malaria difficult to maintain ex vivo. 
The current study focuses on overcoming those limitations by modeling the mode 
of entry of P. vivax into patient-specific, induced pluripotent stem cell (iPSC)-derived 
erythrocyte-lineage cells by showing firstly that DARC is a measurable marker of 
	  	   vii 
susceptibility in vitro via FACS analysis, and that secondly, P. vivax cell culture 
limitations can be bypassed by creating a lentivirus designed to specifically infect 
DARC-expressing cells. To demonstrate the potency of this system, we show that a virus 
expressing the conserved region of the Duffy binding ligand, Duffy binding protein II 
(DBPII), can selectively infect peripheral blood mononuclear cells (PBMCs) that express 
DARC. Moreover, our current study focuses on the development of an iPSC-based 
disease model using patient samples derived from DARC expressing patients (DARC+) 
and DARC negative Sickle Cell Disease (SCD) patients (DARC-). We show that DARC+ 
iPSC-derived erythroid lineage cells express a transient population of DARC-expressing 
cells via FACS analysis, and we explore different protocols to stabilize this unique 
population. We hypothesize that DARC is a stage-specific marker for erythrocyte 
maturation, and we believe that any subset of cells expressing DARC consists of more 
mature erythrocyte-lineage cells. This study then, provides a novel platform by which to 
study malaria infection in a patient-specific manner while bypassing the limitations of 
culturing P. vivax in an in vitro culture system, as well as introducing a new way to 
measure erythrocyte maturation. Successful establishment of such a disease model has 
great implications for in-depth drug screenings for novel therapeutics that target the blood 
stage of the parasitic disease that were previously difficult to validate due to the 
limitations of currently existing models. 
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INTRODUCTION 
  
            Malaria is one of the world’s oldest and most devastating parasitic diseases with 
written records of its existence dating back to 2700 BC in Chinese medical writings. 
However, it wasn’t until 1880 that the French surgeon Charles Louis Alphonse Laveran 
discovered the specific parasite linked to malaria. In the century that followed his 
discovery, much has been elucidated about the disease, but despite these advances, recent 
studies show that over 200 million people a year contract malaria leading to over half a 
million deaths annually (CDC, 2013). 
Malaria is marked by intermittent high fevers, sweats, and rigors—with the most 
severe cases developing splenomegaly and cerebral malaria leading to neurological 
complications and brain damage (Idro et al., 2010). Malaria is brought on by the 
protozoan parasite of genus Plasmodium, which is introduced into the host body by the 
bite of a female Anopheles mosquito. There are four species of Plasmodium that can lead 
to malaria in humans: P. falciparum, P. vivax, P. ovale, and, P. malariae, of which the 
most damaging species is P. falciparum and the most widespread is P. vivax. Despite 
slight differences in the life cycle of each species, it is the repeated lysis and breakdown 
of the erythrocytes within the host’s body that gives malaria its potentially fatal outcome. 
The most susceptible populations to malaria are women and children, with pregnant 
women being at increased risk due to placental sequestration of the parasite (Sappenfield 
et al., 2013). Similarly, young children represent a disproportionate population of those 
fatally infected due to pre-natal exposure and subsequent immunological tolerance 
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(Malhotra et al., 2009; Hviid, 2009). In 2012, there were 627,000 deaths due to malaria, 
and 77% of those deaths occurred in children under five years of age, which equates to a 
death scale of about 1,300 children per day (WHO, 2013).  
 
A BRIEF HISTORY OF MALARIA ERADICATION AND TREATMENT 
Malaria is an invasive disease that has played a role in shaping the development 
of countries and human populations throughout history. Modern day malaria is often 
associated with countries of warmer, wetter climates, but historically, malaria has been a 
disease of the world. It wasn’t until recent implementation of several controversial 
eradication campaigns in the 1940s, most notably the use of the insecticide dichloro-
diphenyl-tricholoroethane (DDT), that malaria has become a non-existent disease in 
North America and Western Europe while still remaining endemic in many developing 
countries (Table 1). 
While the debate remains open as to whether or not the disease is preventable, 
drug development has made malaria curable in countries that do not struggle with an 
endemic presence of the disease. Natural plant derivatives such as artemisinins, quinine, 
and chloroquine have become the corner stones of malaria treatment against both P. 
falciparum and P. vivax species. As the parasite evolves and resistance develops, 
combinatorial treatment of these compounds have proven successful in overcoming most 
malaria infections (Wells, 2013). 
There are, however, major obstacles to worldwide malaria containment and 
eradication. Of notable concern is the emergence of malaria parasites resistant to the most 
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effective malaria drug class: artemisinin-derived drugs, which are able to successfully 
combat the increasing population of multidrug-resistant parasites. While this 
development strikes the hardest blow against efforts to diminish P. falciparum’s impact 
on the developing world, P. vivax parasites have been slower to develop resistance to 
even the oldest drug chloroquine. In fact, its widespread infection rate is due more to a 
unique life cycle than to a rapidly evolving genome (Flannery et al., 2013). 
Perhaps the most difficult obstacle for immunologists and health experts in 
fighting malaria is the location-dependent differences in the epidemiology of the disease. 
Differences in immunogenicity between patients infected from non-endemic countries 
and patients from malaria-exposed populations in endemic countries make creating a 
universally responsive drug or vaccine incredibly difficult (Arama & Troye-Blomberg, 
2014). 
Moreover, there are several limitations to studying the malarial parasite in vitro. 
Current models of infectivity utilize Anopheles mosquitoes as vectors for delivering the 
parasite into host animals (Moll et al., 2008). These studies require specialized facilities 
beyond the scope of conventional laboratories. Furthermore, these systems make use of 
limiting amounts of patient-derived red blood cells, or in the case of animal models, 
colonies of sufficient numbers of experimental animals. To account for exhaustible 
patient samples, immortalized cell lines are often used, which leads to limited genetic 
variability (Golenda et al., 1997). Moreover, certain species of Plasmodium do not 
survive well in tissue culture—namely P. vivax. Adaptation of P. falciparum culture 
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conditions for P. vivax have been met with limited success, due in part to the species’ 
unique life cycle (Trager and Jensen, 1976; Russell et al., 2011).  
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Table 1. Major historical events in controlling worldwide malaria. (Adapted from 
CDC, 2012). 
  
DATE EVENT 
2700 BCE First written record of malaria-like disease described in 
the Chinese medical texts Nei Ching, The Canon of 
Medicine  
340 CE Antifever properties of the Qinghao plant recorded, the 
active ingredient of which is artemisinin, and in 1971 
Chinese scientists synthesize the extract into a series of 
potent antimalarial drugs 
Early 17th Century Spanish missionaries learn from indigenous Indian tribes 
of the New World of an antifever tree bark, which is now 
know as quinine, an incredibly strong antimalarial drug 
1880 – 1890s Several major discoveries link malaria to a multi species  
1886 Camillo Golgi distinguishes different species of malaria 
and links fever state to release of merozoites into the 
blood stream, awarded Nobel Prize in Medicine in 1906 
1897 Ronald Ross discovers that the vector carrying the malaria 
parasite is mosquitoes, awarded Nobel Prize in 1902 
1905 – 1910 The Panama Canal becomes the first civic project where 
an integrated program of insect and malaria control is 
successful  
1934, 1946 Chloroquine is discovered by Hans Andersa and 
established as an antimalarial in 1946 by European and 
US scientists 
1939 Dichloro-diphenyl-tricholoroethane (DDT) is synthesized 
in 1874 by Othmer Zeidler, and brought to use as an 
insecticide in the US and Western European countries, 
awarded Nobel Prize for Medicine 1948 
1951 Malaria is considered eliminated from the US 
1955 
 
 
The World Health Organization (WHO) submits proposal 
for worldwide eradication of malaria using a combination 
of insecticides and antimalarial drug treatment. 
Successes: Countries and nations with temperate climates 
and season malaria transmission (Western Europe) 
Negligible progress: Indonesia, Afghanistan, Haiti, and 
Nicaragua Excluded from eradication campaign: sub-
Saharan Africa 
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THE LIFE CYCLE OF PLASMODIUM VIVAX IN A HUMAN HOST 
Human malaria parasite Plasmodium vivax enters the human host via the bite of a 
female Anopheles mosquito. At this infective stage, the parasite is in its sporozoite form, 
and upon reaching the blood stream, it enters hepatocytes initiating the liver or 
exoerythrocytic stage. Within the liver, P. vivax can undergo one of two differentiations, 
which makes this parasite uniquely different and harder to treat than P. falciparum 
(Ashley et al., 2006). 
While in individual hepatocytes, the Plasmodium parasite undergoes the classic 
differentiation by engaging in several thousand rounds of mitotic replications. P. vivax is 
then released in its merozoite form into the bloodstream, thus initiating the blood or 
erythrocytic stage of the disease. Conversely, and uniquely, P. vivax can also differentiate 
into its hypnozoite stage. As hypnozoites, P. vivax can remain dormant in hepatocytes for 
years causing clinical relapse of malaria. Once activated from the hypnozoite stage, P. 
vivax merozoites are released from hepatocytes in vesicle buds called merosomes, which 
deliver the merozoites to circulating blood cells (Figure 1A). The circulating merozoites 
invade reticulocytes, and within 48 hours, these cells become enlarged to the point of 
lysis. Newly replicated merozoites reenter the blood stream leading to a cyclical 
reinfection and manifestation of the clinical disease state of malaria (Figure 1B) 
(Westenberger et al., 2010). 
During early onset of the blood stage of the disease, a subset of the P. 
vivax merozoites differentiate into mature gametocytes ensuring continued transmission 
of malaria when another Anopheles mosquito takes a blood meal. Once male and female 
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gametocytes enter the mosquito, sexual reproduction of the parasite occurs leading to the 
formation of sporozoites in the salivary glands of the insect. This completes the 
transmission stage and one round of the life cycle of the malaria parasite P. vivax (Figure 
1C) (Flannery et al., 2013). 
Of the three stages of Plasmodium parasite lifecycle, both the liver stage and the 
transmission stage are compelling targets for disease control due to the bottleneck effect 
of disease infection and transmission. Indeed, this is the reason why much of the research 
of P. falciparum focuses on these two stages. However, due to the ability of the 
parasite P. vivax to remain dormant as hypnozoites in the liver, there have been very few 
successful therapies in treating malaria at the liver stage. For example, the only known 
drug capable of eliminating hypnozoite reservoirs is the prodrug primaquine, which when 
metabolized by the liver is thought to take on a toxic form that clears hepatocytes of 
hypnozoites. Obstacles to liver-targeting drugs include patient-specific rates of drug 
metabolism (dose variability), increased resistance to the drug, and more importantly, the 
inability of the parasite to be maintained in cell culture to create vaccines or in-depth 
drug screens (David et al.,1988; Arévalo-Herrera and Herrera, 2001). Instead, global 
treatment of the P. vivax malaria has focused on the blood or erythrocyte stage of the 
disease, which the current study also focuses on by attempting to establish an iPSC-based 
disease model. 
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Figure 1. The life cycle of the Plasmodium vivax parasite in a human host. (A). When 
a female Anopheles mosquito carrying Plasmodium vivax sporozoites bites a human host, the 
sporozoites burrow through the skin and enter the blood stream where they reach the liver. They 
then differentiate into either hypnozoites where they remain latent, or they differentiate into 
merozoites where they actively divide and are released into the blood stream to infect 
reticulocytes. (B). Once P. vivax merozoites have infected reticulocytes, they quickly replicate—
deforming and lysing the cell, which allows the newly released merozoites to either reinfect other 
circulating reticulocytes or differentiate into male and female gametocytes. (C). When another 
mosquito takes a blood meal from the infected human and ingests the gametocytes, the parasite 
undergoes sexual replication within the mosquito leading to the formation of new sporozoites, 
which are stored in the salivary glands of the now infected mosquito (Adapted from Mueller et 
al., 2009). 
 
  
B. Blood Stage 
A. Infection  
and Liver 
Stage 
C. Transmission Stage 
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THE ROLE OF THE DUFFY ANTIGEN CHEMOKINE RECEPTOR (DARC) IN 
THE INFECTION OF CELLS BY THE PARASITE PLASMODIUM VIVAX  
 Patient susceptibility to the merozoite stage of P. vivax is uniquely dependent on 
the phenotype and specific antigen expressed by their Duffy blood group (Hadley & 
Peiper, 1997). The Duffy glycoprotein, also known as the Duffy antigen chemokine 
receptor (DARC), is expressed on the surface of circulating erythrocytes and serves as a 
receptor for chemical signals secreted by red cells during episodes of inflammation. 
DARC is a surface membrane glycoprotein that spans the cell membrane seven times 
with an intracellular C- terminus and an extracellular N-terminus, which serves as a 
binding site for chronic inflammation chemokine (C-C), acute inflammation chemokine 
(C-X-R), and interleukin 8 chemokine (IL-8) (Figure 2A) (Meny, 2010; Novitzky-Basso 
& Rot, 2012). It is expressed in some cells of the liver, and it is found on endothelial cells 
where it acts as a facilitator of neutrophil migration and immune cell activation. The 
parasite P. vivax utilizes DARC as its mode of entry by binding to the N-terminal locus 
causing dimerization of two adjacent DARC complexes to form either a heterotrimer or a 
heterotetramer. Merozoites then invade the cell through the docked and stabilized channel 
(Figure 2B) (VanBuskirk et al., 2004; Peiper et al., 1995). 
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Figure 2. The structure of the DARC complex and its binding to the Duffy Binding 
Protein II of P. vivax. (A). Schematic of the seven transmembrane Duffy receptor protein with 
extracellular N-terminal expressing the different phenotypic antigens which bind to the DBPII 
region of P. vivax. (B). A schematic showing the two possible complexes formed between DARC 
and DBPII. Dimerization of both protein complexes occurs resulting in either reversible 
heterotrimer formation or the irreversible heterotetramer conformation (Adapted from Hadley & 
Peiper, 1997; Batchelor et al., 2014). 
 
   
A. 
B. 
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THE GENETICS OF DARC EXPRESSION IN SUSCEPTIBLE PATIENT 
POPULATIONS 
The FY gene found on chromosome 1 at position q22-q23 encodes the two alleles 
of DARC. FYA and FYB, differ by a single nucleotide polymorphism (SNP) rs2814778 
at nucleotide position 125 (G and A, respectively) and code for the Duffy antigens Fya 
and Fyb, which differ in amino acid residue 42 (glycine and aspartic acid, respectively). A 
second SNP within the erythroid promoter region of the FYB allele codes for active or 
null Fyb expression. Patients expressing the SNP rs2814778 T/C position -33 in the FY 
gene promoter have a null phenotype because the base pair switch at -33T disrupts a 
GATA1 transcription factor binding site by introducing a premature stop codon 
preventing the transcription of Fyb (Meny, 2010). In non-erythrocytes, the gene can still 
be transcribed despite the presence of this mutation, and Duffy positive and Duffy 
negative individuals are still able to mount a normal immune response to instigating 
factors. However, in erythrocytes, homozygous expression of Fyb with the null SNP leads 
to a loss of DARC’s ability to bind chemokines and subsequently prevents P. vivax 
docking and entry into red blood cells (Novitzky-Basso & Rot, 2012).  
 The four resulting phenotypes of the Duffy blood group are Fy (a+b+), Fy (a-b+), 
Fy (a+, b-), and Fy(a-, b-). As shown in Figure 3A, all three phenotypes have varying 
frequencies in different patient populations. In general, Caucasians and Asians have a 
nearly 100% combined frequency of Fya and Fyb antigen expression, while Blacks only 
have a 33% frequency of combined phenotypic expression. This means that 66% of the 
Black population, or populations of immediate African descent, lack a functional Duffy 
	   12 
receptor and are therefore protected from infection by the P. vivax human malaria 
parasite. Thus, P. vivax is not endemic in Africa, but is a disease of Western and Asian 
countries (Figure 3B) (Ashley et al., 2006). 
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Figure 3. The phenotypic frequency of DARC and the corresponding populations 
affected by Plasmodium vivax and P. falciparum malaria. (A). The phenotypic 
frequencies of the four different phenotypes of the codominantly expressed Duffy antigens: Fya 
and Fyb. 100% of Caucasians and Asians express either one or both of the antigens while 2/3 of 
Blacks express the null SNP and lack either antigen. (B). The worldwide populations affected by 
P. falciparum and P. vivax mimics the populations that are genetically susceptible to infection by 
the parasites (Adapted from Dean, 2005; Schwartz et al., 2003). 
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SICKLE CELL DISEASE AND THE CONFERRED PROTECTIVE 
ADVANTAGE AGAINST MALARIA INFECTION 
 The complicated relationship between malaria and sickle cell disease (SCD) has 
been one of great interest to researchers since it is thought that the painful and often lethal 
SCD confers a selective advantage against malaria infection.  
 Sickle cell disease is a hereditary disease caused by a single point mutation in the 
hemoglobin β gene (HbS) leading to the formation of hemoglobin strands, which cause 
erythrocyte sickling (Drasar et al., 2013). The physical deformation of these circulating 
cells causes whole-body episodes of intense pain crises, often with lethal complications. 
Patients suffering from the homozygous expression of the mutation suffer from sickle cell 
anemia and have a shortened life expectancy. In the clinic, disease severity of SCD is 
measured by raised white blood cell (WBC) counts since it is an indicator of the degree 
of inflammation caused by the damaging sickle cells (Platt et al., 1994).  
With respect to the Duffy blood group, it has been shown that Duffy negative 
patients have lowered circulating WBC counts regardless of whether or not the patient 
has the mutation for SCD. It is thought that the reduction in white cell and neutrophil 
counts helps reduce disease severity and that the increased counts in Duffy positive 
patients potentiate inflammation caused by the sickling cells which leads to greater 
complications and pain (Drasar et al., 2013; Afenyi-Annan et al. 2008). 
Whole genome sequencing of unique patient populations homozygous for HbS in Saudi 
Arabia indicate that patients with SCD have a variety of protective malaria resistant 
variant genes (Farrell et al., 2013) (Table 2). The population’s enrichment of malaria 
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resistant SNPs is a compelling argument that the HbS mutation leads to expression of 
several genes that may confer resistance to malaria.  
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Table 2. Table of malaria resistant gene variants in Saudi Arabians. (Adapted from 
Farrell et al., 2013) 
 
  
GENE VARIANT FREQ CHANGE 
MALARIA  
DISEASE 
RESISTANCE 
DARC rs2814778 0.86 GATA Binding Site 
Duffy blood group system,  
FY(a-b-) phenotype 
DARC rs12075 0.04 G42D Duffy blood group system, FYA/FYB polymorphism 
FCGR2B rs1050501 0.36 I225T Regulation of antibody  production 
ATP2B4 rs4951074 0.25  Main calcium pump of  erythrocytes 
HLA-B HLA*B*53:01 0.11  Immune Response 
CD36 rs3211861 0.1 Frame-shift Adhesion of infected RBCs 
CD36 rs1334512 0.32 UTR-5 Adhesion of infected RBCs 
CD36 rs144344249 0.1 N53S Adhesion of infected RBCs 
CD36 chr7:80286010 0.03 T92M Novel and probably damaging 
CD36 chr7:80300294 0.03 S198P Novel and important target 
ABO rs8176719 0.25  Blood group type O allele 
TIRAP rs8177374 0.18 S180L Innate immune system 
HBB rs334 1 E7V HbS 
HBA2 rs63750067 0.03 3'UTR Alpha-thalassemia- 2nondeletional 
MARVELD3 rs2334880 0.93 Intergenic  
SLC4A1 rs5036 0.07 K56E Band 3 Memphis 
SLC4A1 rs5035 0.07 D38A  
G6PD rs5030868 0.29 S188F G6PD Mediterranean 
G6PD rs1050829 0.11 N126D G6PD_A+ 
G6PD rs1050828 0.07 V68M G6PD A- 
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THE USE OF INDUCED PLURIPOTENT STEM CELL TECHNOLOGY TO 
ESTABLISH DISEASE MODELS 
The discovery of human embryonic stem cells (hESCs) has helped to elucidate 
developmental pathways, shed insight into cell plasticity, and usher in a new frontier for 
regenerative medicine.  Based on early research that focused on somatic cell nuclear 
transfer (SCNT), it is now known that the genetic content of a committed somatic cell can 
be “restarted” to express genes favoring a pluripotent ESC-like state (Rodriguez-Osorio 
et al., 2012).  Research into this reprogramming process reveals that pluripotency can be 
initiated by introducing four transcription factors, Oct4, Klf4, Sox2, and cMyc, into a 
somatic cell to achieve an embryonic stem cell-like cell (Takahashi et al., 2007).  
These induced pluripotent stem cells (iPSCs) are characteristically similar to 
hESCs while also solving many of the technical and ethical limitations of using hESCs in 
culture (Puri & Nagy, 2012). iPSCs are created from easily obtained somatic cells, which 
are reprogrammed into pluripotent stem cells.  From the viewpoint of an experimental 
platform, iPSCs recapitulate the exact genetic background of the subject from whom they 
are derived; therefore, eliminating any potential immunogenic response in the future, 
which carries great promise for the use of iPSCs in regenerative medicine.   
This conservation of genetic information makes iPSC technology a compelling 
platform for patient-specific disease modeling of complex diseases. Prior to iPSC 
technology, in vitro disease modeling was limited to immortalized cell lines, patient 
tissue samples, and utilization of non-human model organisms. The constraints of such 
options include the limited number of hESC cell lines, lack of genetic variability within 
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immortalized cell lines, inability to map disease progression due to difficulty in obtaining 
tissue samples, inaccurate depiction of disease in post-mortem tissues, and organism and 
species variability between model organisms (Inoue et al., 2014). In our research, we use 
the STEMCCA Cre-excisable polycistronic lentiviral cassette, which introduces the four 
reprogramming factors to our donor somatic cells (Figure 4) (Sommer et al., 2012). 
These reprogrammed iPSCs can be differentiated into tissues of interest to model effects 
of early disease progression in vitro, as well as establish a patient-specific drug-screening 
platform for novel therapeutics (Figure 5) (Jang et al., 2012).  
We have previously shown that iPSC-based disease modeling can be used to 
recapitulate a multi-systemic disease in vitro and validate current drugs in FDA trial for 
transthyretin (TTR) amyloidosis (Leung et al. 2013). Using iPSCs created from the 
PBMCs of a patient with the mutation, we show through directed differentiation that 
iPSC-derived hepatocytes secrete the aberrant TTR protein, which leads to increased cell 
damage and cell death in patient-matched iPSC-derived cardiomyocytes and motor-
neuron lineage cells (Supplemental Figure 1), and that small molecule drugs that 
stabilize the formation of the homotetramer conformation of the protein help to increase 
cell survivability and ameliorate the effects of the accumulation of aberrant ATTR fibrils 
(Supplemental Figure 2).  
A similar approach is used in the current study to model mode of entry of the 
human malaria parasite P. vivax in iPSC-derived erythrocytes. An iPSC-based model for 
this species of malaria helps bypass many of the limitations of existing models. It 
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generates an inexhaustible patient-specific population allowing for a more controlled 
investigation into the genetics of the disease.  
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Figure 4. Schematic of the STEMCCA Cre-excisable polycistronic lentiviral vector. 
The STEMCCA cassette is flanked by loxp cutsites allowing the viral component to be removed 
from the genome once the four reprogramming factors (Oct4, Klf4, Sox2, and cMyc) have been 
incorporated into the donor genome (Adapted from Sommer et al., 2012). 
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Figure 5.  Personalized medicine: using iPSC-based disease modeling as a clinical 
trial in a test tube. A peripheral blood sample is taken from a patient with a genetic disease 
and then spun down to separate the peripheral blood into its plasma, buffy coat, and red blood cell 
components. Because the buffy coat contains nucleated mononuclear cells, this layer is collected 
and the mononuclear cells are exposed to STEMCCA, a lentiviral vector containing the four 
reprogramming factors: Oct4, Klf4, Sox2, cMyc; thus, giving rise to patient-specific iPSCs, 
which are genetically identical to the patient and the disease. These pluripotent cells can then be 
directly differentiated into target cells of tissues that manifest this disease to help establish models 
of disease progression in vitro as well as provide an unlimited source of disease and patient-
matched cells for drug screening for novel therapeutics. Information gleaned from this process 
can then be used to treat the specific patient with a drug cocktail that their iPSC-derived cells 
responded to in vitro (Figure donated from SS Rozelle). 
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RECREATING THE HEMATOPOIETIC HIERARCHY OF ERYTHROID CELL 
DEVELOPMENT IN VITRO 
The process of blood development in vivo is a highly regulated and efficient 
process allowing for millions of blood cells to be replenished daily. In the developing 
human, hematopoiesis occurs in two waves. The first wave occurs in young embryos 
around day 15 of human development. Cells from blood islands located in the embryonic 
yolk sac undergo primitive hematopoiesis leading to a transient population of 
hematopoietic cells-- including nucleated erythrocytes that express embryonic 
hemoglobin. The second wave of hematopoiesis occurs around day 30 of embryonic 
development and is considered the definitive hematopoietic stage. A small population of 
hematopoietic stem cells located within the bone marrow gives rise to all the cells in the 
hematopoietic lineage including enucleated erythrocytes that express later forms of adult 
hemoglobin (Robin et al., 2000).  
These natural processes are much harder to recapitulate in vitro because the 
molecular mechanisms that govern differentiation into the cells of the hematopoietic 
lineages are much harder to define in the absence of the bone marrow niche. Much 
research has gone into differentiating a stable population of these cells but they are 
limited in their dependence on co-culturing with a feeder layer and low output in cell 
yield l(Table 3).  
We have previously shown that a large population of erythroid-lineage cells can 
be created from iPSCs in feeder-free context by exploiting the role of the aryl 
hydrocarbon receptor (AHR) with the agonist molecule 6-formylindolo[3,2-b]carbazole 
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(FICZ) (Smith & Rozelle et al.,  2013).  The present study uses this directed 
differentiation protocol to establish an iPSC-based platform to generate erythroid-lineage 
cells to help model mode of entry of P. vivax into patient-specific red blood cells. As P. 
vivax has not been successfully maintained in culture, this study also attempts to solve 
this limitation by creating a virus that might mimic the interaction of the Duffy binding 
ligand to the DARC receptor, which facilitates P. vivax merozoite entry. 
	   24 
Table 3. Known methods of hematopoietic differentiation. Comparison of previously 
published protocols for erythroid-lineage cells showing that many are dependent on coculture 
with feeder cells while also producing a low yield of cells—some of which are even 
immeasurable “N/M” (Adapted from Chang et al., 2011) 
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METHODS 
 
INDUCED PLURIPOTENT STEM CELL DERIVATION AND CULTURE 
Induced pluripotent stem cell (iPSC) induction was achieved using the 
hSTEMCCA lentiviral vector as previously described (Sommer et al., 2012). Peripheral 
blood mononuclear cells (PBMCs) were used as source material for iPSC production. 
Samples were centrifuged at 37oC for 25 minutes at 1800 rcf and the resulting buffy coat 
was collected in a 15ml conical tube. Cells were resuspended in 2ml of expansion 
medium, consisting of QBSF-60 (Quality Biological 160-204-101), 50ng/ml hSCF (R&D 
255-SC-010), 10ng/ml hIL-3 (R&D 203-IL-010), 2U/ml hEPOgen (Amgen), 40ng/ml 
hIFG-1 (R&D 291-GI-050), 50μg/ml Ascorbic Acid (Sigma A4403), 100μg/ml 
Primocin (Invivogen ant-pm-2) and 1μM Dexamethasone (Sigma D4902). After 8-9 
days, polybrene was added to the medium (5μg/ml) and the hSTEMCCA lentivirus was 
added to the culture at a multiplicity of infection (MOI) ranging from 1-10. After 24 
hours, the inoculated culture was spun at 2250g for 90 minutes and the polybrene media 
was discarded. The cells were then plated onto irradiated Mouse Embryonic Fibroblasts 
(iMEFs) and cultured for roughly 7 days in “iPSC media” that included DMEM F12 
(Invitrogen 11330057), 10ng/ml bFGF (R&D 233-FB-025), 1ng/ml Rho Kinase Inhibitor 
(Cayman Chemical 10005583), 20% Knock-out Replacement Serum (KOSR) (Invitrogen 
10828028), and 100μg/ml Primocin. Clones were then picked and expanded for long-
term culture. 
 
	   26 
ADAPTING iPSCS TO FEEDER FREE mTeSR BASED CULTURE 
iPSCs derived from the hSTEMCCA lentiviral vectors were transitioned to a 
feeder free based culture system by removing “iPSC Media” (as described above) from 
iPSCs plated onto irradiated iMEFs, washed with PBS, and dissociated using the enzyme 
Collagenase Type IV (Invitrogen 17104019). The wells were washed again with PBS, 
introduced to mTeSR1 Complete Kit for hES Maintenance Media (Stem Cell 
Technologies 5850) with 100mg/ml Primocin, scraped off the plate with a cell scraper, 
and brought to a single cell suspension and plated in a 1:1 ratio onto a Matrigel matrix 
(Fisher CB-40234B) coated well of a 6 well plate. Cells were kept at high confluency 
while lines stabilized and were passaged thereafter with 1mg/ml of the dissociation 
enzyme Dispase (Stem Cell Technologies 7923) with daily changes of mTeSR. 
 
DIRECTED DIFFERENTATION OF iPSCs INTO HEMATOPOIETIC CELLS 
mTeSR-adapted iPSCs were plated onto matrigel coated 6 well plates as 
described above. After two days, mTeSR media was replaced with media cocktails 
designed to initiate hematopoietic specification. As previously described in our 
hematopoietic protocol (Smith et al. 2013): D0-1 media: RPMI (Invitrogen A1049101) 
supplemented with 5ng/ml hBMP-4 (R&D 314-BP), 50ng/ml hVEGF (R&D 293-VE), 
25ng/ml hWnt3a (R&D 287-TC) and 10% KOSR; D2 media: RPMI supplemented with 
5ng/ml hBMP-4, 50ng/ml hVEGF, 20ng/ml bFGF and 10% KOSR;  D3 media: StemPro 
34 (Invitrogen 10639011), 5ng/ml hBMP-4, 50ng/ml hVEGF, and 20ng/ml bFGF; D4-5 
media: StemPro 34, 15ng/ml hVEGF, and 5ng/ml bFGF; D6 media: 74% IMDM 
	   27 
(Invitrogen 12330061), 24% Hams F12 (Mediatech 10-080-CV), 1% B27 supplement 
(Invitrogen 12587-010), 0.5% N2-supplement (Invitrogen 17502-048), 0.5% BSA 
(Sigma A3059), 50ng/ml hVEGF, 100ng/ml bFGF, 100ng/ml hSCF (R&D 255-SC), 
25ng/ml hFlt3 Ligand (R&D 308-FKN);  D7 media: 74% IMDM, 24% Hams F12, 1% 
B27 supplement, 0.5% N2-supplement, 0.5% BSA, 50ng/ml hVEGF, 100ng/ml bFGF, 
100ng/ml hSCF, 25ng/ml hFlt3 Ligand, 50ng/ml hTPO (Genentech G140BT), 10ng/ml 
IL-6 (R&D 206-IL), 0.5U/ml hEPOgen and 0.2 mM 6-formylindolo[3,2-b]carbazole 
(FICZ) (Santa Cruz SC300019). After Day 7, 0.5ml of Day 7 media was added to the 
culture daily without aspirating the media from the previous day.  All base media mixes 
included 2mM L-Glutamine (Invitrogen 25030081), 4x10-4M Monothioglycerol (Sigma 
M1753), 100mg/ml Primocin, and 50μg/ml Ascorbic Acid.  Cells in suspension were 
collected and assayed at Days 10-15 or split for long-term culture.   
  
ERYTHROID-LINEAGE SPECIFICATION OF MEPS 
Erythroid-lineage cells were generated from Day 15 MEPS by first collecting, 
spinning, and resuspending the cells in Erythroid Maturation Media (EMM) containing 
IMDM, 10% Plasmanate (human plasma mimetic, Talecris Bio., NC), 10% PFHM-II 
(Protein-Free Hybridoma Medium, Gibco 12040077), 2U/ml hEPOgen, 30mg/ml 
Transferrin (R&D 2474-TR), 50μg/ml ascorbic acid, 4x10-4M Monothioglycerol, 2mM 
L-Glutamine, and100mg/ml Primocin. The EMM suspension cell mix were then plated in 
a tissue culture treated plate or onto a mitomyocin-C treated bone marrow stromal layer 
line (OP9) when applicable.  
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DUFFY BINDING LIGAND LENTIVERAL VECTOR GENERATION AND 
APPLICATION 
PCR primers were designed to amplify the Duffy Binding Protein II (DBPII) gene 
from reporter construct pUC57-Ampicillin Resistance (synthesized by Genewiz) with 
integrated NotI and BamHI cut sites at the 5’ and 3’ ends respectively. The DBPII 
sequence: 
5’tttgcggccgccatggctattataaatcatgcttttcttcaaaatactgtaatgaaaaactgtaattataagagaaaacgtcgggaaagagatt
gggactgtaacactaagaaggatgtttgtataccagatcgaagatatcaattatgtatgaaggaacttacgaatttggtaaataatacagacaca
aattttcatagggatataacatttcgaaaattatatttgaaaaggaaacttatttatgatgctgcagtagagggcgatttattacttaagttgaataac
tacagatataacaaagacttttgcaaggatataagatggagtttgggagattttggagatataattatgggaacggatatggaaggcatcggat
attccaaagtagtggaaaataatttgcgcagcatcttaggaactggtgaaaaggcccaacagcatcgtaaacagtggtggaatgaatctaaag
cacaaatttggacagcaatgatgtactcagttaaaaaaagattaaaggggaattttatatggatttgtaaaataaatgttgcggtaaatatagaac
cgcagatatatagatggattcgagaatggggaagggattacgtgtcagaattgcccacagaagtgcaaaaactgaaagaaaaatgtgatgg
aaaaatcaattatactgataaaaaagtatgtaaggtaccaccatgtcaaaatgcgtgtaaatcatatgatcaatggataaccagaaaaaaaaatc
aatgggatgttctgtcaaataaattcataagtgtaaaaaacgcagaaaaggttcagacggcaggtatcgtaactccttatgatatactaaaacag
gagttagatgaatttaacgaggtggcttttgagaatgaaattaacaaacgtgatggtgcatatattgagttatgcgtttgttccgttgaagaggcta
aaaaaaatactcaggaagttgtgacaaattaaggatccaaa 3’ 
The restriction enzyme digested PCR product was then inserted into an HDM-VSVG2 
plasmid by excision of the VSVG2 gene and ligation of the NotI and BamHI digested 
DBPII gene. HDM-DBPII and VSVG pseudotyped lentivirus was packaged containing 
the pHAGE-EF1a-ZsGreen-WPRE vector as previously described using the cell line 
293T (Sommer et al., 2012). Briefly this includes PBMCs were infected overnight and 
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subsequent ZsGreen gene expression was monitored by fluorescence microscopy and 
flow cytometry.  
 
QUANTITATIVE RT-PCR 
RNA was extracted using the RNeasy kit (Qiagen 74104) and cleaned of residual 
DNA using a DNase based DNA-free kit (Ambion AM1906). cDNA was made from the 
RNA samples using the High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems 4368814). Quantitative (real time) PCR amplification of cDNA was 
performed using Taqman probes for CD235 (Life Technologies GYPA Hs00266777_m1) 
and DARC (Life Technologies Hs01011079_s1) and run on the Applied Biosystems 
StepOne machine. Gene expression was normalized to Beta-actin (Hs99999903_m1). 
 
FLOW CYTOMETRY 
From the differentiations, 105 cells were collected, spun down at 1000 rpm for 5 
minutes, and re-suspended in 0.5% bovine serum albumin (BSA) (Sigma A3059) in PBS. 
Samples were then incubated at 30 minutes on ice with human antibodies for CD235 - PE 
(R&D FAB12281P), DARC – FITC (R&D FAB4139F) and DARC – APC (R&D 
FAB4139A), washed and spun at 3300 rpm for 7min, and re-suspended with 1ug/ml 
propidium iodide (BD Biosciences 56463). Cell samples were run on a BD FACScalibur 
using Cellquest Pro software, and data was analyzed via FloJo 8.7. 
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RESULTS 
 
DARC IS DETECTABLE IN VITRO IN PERIPHERAL BLOOD  
In order to successfully establish an in vitro model of Plasmodium vivax infection, 
a system of quantifying and measuring susceptibility to infection must be established. It 
was found that the presence of the Duffy antigen chemokine receptor (DARC) can be 
detected in peripheral blood samples of patients who phenotypically express the Duffy 
antigens using antibody staining and FACS analysis. Conversely, DARC was 
undetectable in peripheral blood samples of patients who express the null phenotype of 
the Duffy antigen (Figure 6).  The peripheral blood samples were dual stained with a 
DARC specific antibody tagged with fluorescein isothiocyanate (DARC-FITC) and a 
Glycophorin-A antibody tagged with phycoerythrin (CD235a-PE), and the cells were 
analyzed using fluorescence-based flow cytometry.  
In the first set to experiments, we stained peripheral blood for Glycophorin-A 
(CD235a), the hallmark marker of the erythroid lineage. As expected all cells expressed 
CD235a irrespective of DARC expression. However, when using the DARC antibody, 
only the peripheral blood cells that came from a DARC+ patient stained positive for 
DARC expression, verifying that our patient was indeed DARC+, and that our antibody 
staining protocol could discern between DARC+ and DARC- blood samples. 
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Figure 6. Presence of the Duffy antigen can be accurately detected by FACS analysis 
of DARC positive and DARC negative peripheral blood samples with CD235a-PE 
and DARC-FITC antibodies. Duffy expressing peripheral blood samples were DARC 
positive and CD235a positive in both single and dual antibody staining. DARC negative 
peripheral blood was only CD235a positive. Cells were live gated using propidium iodide and 
were selected as a side population based on cell size.
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REPORTER LENTI-VIRUS PSEUDOTYPED WITH DBP-II VALIDATES 
SUSCEPTIBILITY TO INFECTION OF PERIPHERAL BLOOD 
MONONUCLEAR CELLS 
 Plasmodium vivax has yet to be successfully maintained in culture (Golenda et al., 
1997) so an in vitro model of erythroid-lineage cell susceptibility to P. vivax entry 
requires a more targeted approach to bypass protozoan culturing. During the blood stage 
of the disease in vivo, merozoites of the parasite enter reticulocytes by binding to the 
Duffy antigen chemokine receptor (DARC). The Duffy binding ligand (DBL) on the 
surface of the merozoite has one crucially conserved region known as the Duffy binding 
protein II region (DBPII), which has been shown to bind selectively to the Duffy antigens 
of DARC-expressing cells (VanBuskirk et al., 2004).  
 A lentivirus with constitutive ZsGreen (EF1α –ZsGreen-WPRE) expression was 
created as a way to measure successful infection of our cell population. The glycoprotein 
of the outer envelope of the virus was pseudotyped to DARC expression by using an 
HDM-DBPII viral packaging plasmid. Expression was controlled for by creating a 
ZsGreen lentivirus with HDM-VSV-G envelope glycoprotein plasmid, a protein 
pseudotyped for universal infection of any cell that expresses the ubiquitous receptor for 
VSV-G (Figure 7).  
Increasing the concentration of HDM-DBLII viral envelope plasmid to the other 
viral packing plasmids from a 1:1 to 2:1 and 5:1 ratio leads to a decrease in infection 
efficiency as seen by a decrease in the number of peripheral blood mononuclear cells 
(PBMCs) with subsequent ZsGreen expression as measured by FACS analysis . This 
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suggests that viral particles expressing DBPII are either created more efficiently or are 
more stable using a 1:1 ratio  (Figure 8).  
 Reporter virus pseudotyped for universal expression with the polytropic envelope 
protein VSV-G was shown to infect both DARC + and DARC – PBMCs. Conversely, 
reporter virus pseudotyped for DARC expression with the envelope protein DBPII (1:1 
ratio) could only selectively infect DARC + PBMCs (Figure 9). This indicates that the 
DBPII virus is able to mimic in vitro the protozoan selectivity of P. vivax for DARC-
expressing blood cells that is seen in vivo.  
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Figure 7. Diagram of VSV-G and Duffy Binding Ligand II studded lentiviruses. 
VSV-G gives the lentivirus the ability to bind to any cell surface and infect that cell. DBLII as an 
outer envelope glycoprotein limits the viral infectivity only to the cells that are susceptible, which 
are the cells that express the Duffy antigen chemokine receptor (DARC). 
VSV-G 
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Figure 8. FACS analysis of the infectivity of lentiviruses packaged with varying 
concentration of Duffy Binding Protein II with DARC expressing peripheral blood 
mononuclear cells. Varying concentrations of the DBPII viral envelope was added to other 
viral packaging plasmids crucial to viral creation at a 1:1 (1x), 2:1 (2x), and 5:1 (5x) ratio. 
Successful viral infection was measured by integration of ZsGreen reporter construct into infected 
PBMCs, and fluorescence was measured by FACS analysis. The positive control for infectivity is 
VSV-G studded lentivirus. Cells were live gated using propidium iodide and were selected as a 
side population based on cell size.
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Figure 9. DBPII lentivirus selectively infects DARC expressing peripheral blood 
mononuclear cells. DBPII at a 1x concentration infects only DARC expressing PBMCs 
while being unable to infect PBMCs missing DARC. Cells were live gated using propidium 
iodide and were selected as a side population based on cell size.  
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CREATION OF DARC-SPECIFIC INDUCED PLURIPOTENT STEM CELLS 
AND THEIR DIRECTED DIFFERENTIATION INTO ERYTHROID-LINEAGE 
CELLS 
 In order to create a patient-specific disease model of malaria susceptibility and red 
cell infectivity, PBMCs of DARC negative patients and DARC positive patients were 
infected with the STEMCCA lentiviral vector and reprogrammed following previously 
established protocols (Sommer et al., 2012). Irrespective of Duffy phenotype, the 
resulting cells expressed markers of pluripotency as shown by fluorescent antibody 
staining (Figure 10A). Karyotype analysis of both DARC-specific iPSC lines show 
normal karyotype with no abnormalities in chromosome count or chromosome length 
(Figure 10B).  
DARC-specific iPSCs were pushed down a hematopoietic lineage using a step-
wise, cytokine-driven differentiation pathway that mimics blood development in vivo 
(Smith & Rozelle et al., 2013). Early steps of this 2D cell-culture protocol hinge upon 
brief exposure of iPSCs to morphogenetic factors involved in embryonic patterning 
(Wnt3a) and hematopoietic specification (BMP-4). Introduction to more lineage-specific 
cytokines help drive the cell population toward a hematopoietic progenitor cell fate 
(Figure 11A). By day 15, these hematopoietic progenitor cells stain positive for CD235a 
Glycophorin-A and CD41 integrin alpha chain 2b, markers of erythroid and 
megakaryocyte lineages, respectively. Thus, indicating that the cell population consists of 
a bipotential megakaryocyte erythroid progenitor (MEP) cell (Figure 11B).  
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Introduction of the aryl hydrocarbon receptor (AHR) agonist, FICZ, drives MEP 
specification and expansion, and prolonged exposure to FICZ helps promote 
erythropoiesis. By day 13, progenitor cells express CD71, the transferrin receptor, an 
early transient marker of erythropoiesis. Chronic exposure the AHR agonist increases 
expression of CD235a, Glycophorin-A, a marker of late erythropoiesis (Figure 11A). By 
day 60 with steady AHR hyperactivation, cells no longer express markers of the 
bipotential MEP cell, seeming to favor the erythroid lineage as evidenced by loss of 
CD41 expression (Figure 11B). As these cells mature in vitro, cell pellets appear red, a 
sign of functional hemoglobin content (Figure 11C). 
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Figure 10. iPSCs generated from disease specific sickle cell anemia patients are 
pluripotent and have a normal karyotype.  (A). iPSCs generated from both DARC+ and 
DARC- sickle cell peripheral blood samples were stained for pluripotency markers SSEA4 and 
Tra-1-81 as well as DNA by DAPI.  (B). These cells also have a normal karyotype. 
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Figure 11. DARC+ and DARC- iPSCs can be differentiated down a hematopoietic 
lineage. (A). Differentiation schematic with matching photos of the 2D cell-culture protocol that 
mimics in embryonic development of blood in vivo. (B). Both DARC+ and DARC- iPSCs are 
capable of being differentiated down a hematopoietic lineage and the resulting cells express dual 
positivity for CD235a and CD41 suggesting a megakaryocyte erythroid progenitor cell as shown 
by FACS analysis on Day 15 of the differentiation protocol. Cells were live-gated using 
propidium iodide and were selected as a side population based on cell size.   
B. 
A. 
ISOTYPE                    DARC+         DARC- (Sickle Cell)  
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Figure 12. Continuous exposure to FICZ is permissive to erythroid-lineage cell 
development. (A). With continued exposure to AHR, cells express the early marker for 
erythropoiesis CD71, the transferrin receptor and increased expression of late marker of 
erythropoiesis CD235a, Glycophorin-A as evidenced by FACS anaylsis. (B). Cells lose 
megakaryocyte fate with chronic exposure to AHR as shown by FACS analysis. Cells were live-
gated using propidium iodide and were selected as a side population based on cell size. (C). The 
resulting hematopoietic erythroid lineage cells are red when pelleted due to functional 
hemoglobin content.   
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(Sickle Cell) 
C. 
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A SUBSET OF DARC EXPRESSING PATIENT-SPECIFIC iPSC-DERIVED 
ERYHROID-LINEAGE CELLS TRANSIENTLY EXPRESS DARC 
 iPSCs derived from DARC expressing patients were differentiated down a 
stepwise cytokine-driven differentiation protocol and transiently express the Duffy 
receptor early on in the differentiation on day 13 (Figure 13). However, this population 
cannot be maintained and cells either die or lose DARC expression by day 19. It is 
theorized that DARC is a stage specific marker for more mature erythrocyte lineage 
stages but later time points in our traditional hematopoietic protocol do not seem to 
sustain this population.  
To adjust for this, cells were grown on a feeder bone marrow niche stromal layer 
known as OP9s later in the differentiation. OP9s promote maturation by secreting a 
variety of factors for hematopoietic erythroid lineage maintenance (Choi et al., 2012). 
Cells were introduced to a cytokine-depleted media known as our Erythroid Maturation 
Media (EMM), which contained erythropoietin and transferrin for red blood cell 
maturation. After several days in the original differentiation scheme, cells were moved 
onto EMM+OP9 growth conditions. The resulting cells show greater hemoglobin content 
after seven days as evidenced by benzidine and Wright-Giemsa staining (Figure 14).  
Quantitative PCR shows that erythroid-lineage cells derived from iPSCs from 
patients who express DARC exhibit a peak in DARC transcript at the mRNA level 
around day 15 when grown in the normal hematopoietic media followed by a subsequent 
decline in DARC expression across later time points. However, cells moved onto an OP9 
stromal layer in EMM exhibit increased DARC transcript relative to beta-actin transcript 
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expression (Figure 15A). Despite an increase at the transcript level, no increase in 
DARC expression at the protein level is detected when cells were stained for DARC and 
analyzed by FACS analysis. (Figure 15B).  
It has been suggested that since the bone marrow is an oxygen-restricted niche, 
many of the stem cells that repopulate the hematopoietic lineage favor hypoxic growth 
conditions (Suda et al., 2011). The DARC expressing iPSC-derived erythroid-lineage 
cells were grown on OP9 in EMM in both hypoxic and normoxic growth conditions to 
help promote maturation and expansion. However, after 7 days in low oxygen, the cells 
did not show an increase in DARC expression as evidenced by FACS analysis for DARC 
expression (Figure 16).  
The current model, then, is limited by the ability to generate DARC expressing 
iPSC-derived erythroid lineage cells. If, as thought, DARC is a stage specific marker 
present in more mature erythroid-lineage cells, then the current protocol favors expansion 
of an earlier population of immature erythrocytes.  
 
	   44 
 
 
Figure 13. FACS analysis of DARC+ iPSC-derived erythroid lineage cells for DARC 
and CD235a. Cells were stained for DARC and CD235a surface markers at varying timepoints 
along a differentiation. On day 13, a small subset of DARC positive cells appears which 
disappears by day 19. These cells also positive for CD235a. Cells were live gated using 
propidium iodide and were selected as a side population based on cell size.
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Figure 14. Hemoglobin content of cells grown in different tissue culture conditions. 
DARC+ iPSC-derived erythroid cells grown in normal hematopoietic media show minimal 
hemoglobin content as shown by benzidine staining. Six days on an OP9 stromal layer in 
erythroid maturation media (EMM) increases hemoglobin content as shown by dark black in the 
benzidine staining. 
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Figure 15. Duffy antigen transcript within our iPSC-derived erythroid cells is 
transient but can be increased in maturation conditions (OP9, EMM) but cannot be 
detected by FACS analysis. (A). qPCR analysis looking at DARC expression reveals a 
transient increase in DARC early in the differentiation (day 16) that is lost by day 29. Cells grown 
in maturation conditions shows increase in DARC expression. (B). This increase however, cannot 
be seen in via FACS analysis.  Cells were live gated using propidium iodide and were selected as 
a side population based on cell size. 
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Figure 16. Hypoxic conditions do not increase DARC expression and adversely 
effect cell survivability. Duffy expressing iPSC-derive erythroid-lineage cells grown in 
hypoxic conditions in maturation conditions (OP9, EMM) do not show increase in DARC 
expression as shown by FACS analysis. Moreover, cells seem to survive better in normoxic 
conditions. Cells were live gated using propidium iodide and were selected as a side population 
based on cell size. 
DARC-APC 
C
D
23
5-
PE
 
DARC+ Day 
30, OP9 EMM, 
Hypoxia 
0.
59
0.
18
0.
99
98
.2
0.
63
0.
12 1
98
.2
0.
02
8
5.
21
94
.2
0.
57
0.
01
4
4.
55
94
.7
0.
69
0.
03
3
1.
43
e-
3
0.
03
6
99
.9
0.
67
0.
01
0.
04
5
99
.3
6.
04
e-
3
0.
04
7
66
.4
33
.5
0.
34
0.
28
77
.8
21
.5
DARC+ Day 
30, OP9 EMM, 
Normoxia 
 
IS
O
TY
PE
 
 
D
A
R
C
-A
PC
 
 
C
D
23
5-
PE
 
 
D
U
A
L 
 
	   48 
DISCUSSION 
 
This study focused on establishing an iPSC model of Plasmodium vivax malarial 
infection into erythroid cells. Past attempts at studying P. vivax have been hampered by 
the parasite’s difficult life cycle and its inability to be continually cultured in a laboratory 
setting. Moreover, host tissues in the laboratory consist of patient samples, which are 
exhaustible, and immortalized cell lines, which represent a limited gene pool. Due to the 
lack of a sustainable model, drug screening for novel therapeutics against P. vivax has 
been limited. Here we attempt to create an in vitro model that bypasses many of the 
limitations of both live parasite culture and exhaustible tissue samples. Furthermore we 
are able to create an unlimited supply of cells with disease-specific genotypes such as 
Duffy expressing, Duffy negative, and sickle cell anemia.   
 
INFECTION OF SUSCEPTIBLE BLOOD CELLS CAN BE RECAPITULATED 
IN VITRO BY USING A LENTIVIRAL VECTOR PSEUDOTYPED FOR CELLS 
EXPRESSING DARC  
 In order to establish an in vitro model of infection, a platform had to be created by 
which to quantify and measure the amount of DARC expression as a measure of cell 
susceptibility to infection. We established a FACS based antibody staining platform with 
which to detect cell susceptibility based on the presence of DARC. Dual positivity for 
DARC and CD235a Glycophorin-A indicates that positive cells are of an erythroid 
lineage and express the Duffy antigen on their cell surface membrane.  
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Our previous work has utilized lentiviral vectors with universal infectivity by 
using a VSV-G outer envelope glycoprotein. To bypass P. vivax parasitic culture, a 
lentiviral vector was engineered to express DBPII to specifically target DARC-expressing 
cells by replacing VSV-G with the conserved binding domain of the Duffy binding 
ligand. It was found that the virus is not only successful in infecting peripheral blood 
mononuclear cells (PBMCs), but that it also selectively infects those PMBCs that express 
DARC. Duffy negative PBMCs do not show integration of the ZsGreen gene, which is 
the read out for successful infection. 
 This lentivirus-based model of P. vivax infection lends itself to studying the 
uniquely specific factors that might disrupt the docking and binding of the parasite to an 
erythroid cell. It also bypasses the need for culturing the parasite in a laboratory setting 
that previously limited in-depth investigation into parasite eradication. Vaccines targeting 
the binding of the merozoite stage of the parasite to circulating reticulocytes have been 
highlighted as a potential way to treat and prevent the spread of P. vivax based malaria. 
Many of these vaccines use antibody blocking to sterically compete with the binding of 
the Duffy binding ligand to DARC (Arévalo-Herrera and Herrera, 2001; David del 
Portillo et al., 1988; Ntumngia and Adams, 2012). Because the virus can be easily created 
and reproduced, it can be used to screen vaccines against cell lines expressing DARC to 
validate potential small molecules or antibody-blocking therapies. Once DARC 
expression in our differentiated iPSC-based model is stabilized,  this platform can be used 
to screen vaccines against a variety of genetic backgrounds in susceptible patient 
	   50 
populations—particularly those patient populations that come from malaria-endemic 
countries that have a history of resistance to many novel therapeutics.  
 
PATIENT-SPECIFIC iPSCS CAN BE DIFFERENTIATED INTO ERYTHROID-
LINEAGE CELLS 
 It was found that iPSCs can be successfully reprogrammed from DARC+ and 
DARC- patient populations. These patient-specific iPSCs can be pushed down a 
hematopoietic fate where they express markers for a megakaryocyte erythroid progenitor 
cell (CD235a and CD41). Moreover, the erythroid-lineage cells express the characteristic 
redness of a red blood cell indicating increasing hemoglobin content, which is verified by 
positive benzidine staining. 
 The hematopoietic protocol allows for the culturing and capturing of serum- and 
feeder cell-free hematopoietic erythroid-lineage cells. By utilizing the role of AHR in this 
cellular developmental process, expansion and specification of these cell lineages can be 
controlled with a high yield of a pure cell population. This highly efficient protocol has 
allowed for the creation of DARC-specific iPSC-derived erythroid-lineage cell 
populations. These lines are patient-specific, and therefore disease-specific. Thus, this 
platform provides a means in which to expand our malaria infectivity model to include 
the role of Sickle Cell Disease (SCD) on the genetics behind the disease. Our DARC 
negative iPSCs come from patients with the homozygous HbS mutation for sickle cell 
anemia. It has been shown that the sickle cell mutation that causes HbS has been linked 
to an increase in mutations and SNPs that protect these patients from malarial infection 
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(Farrell et al., 2013). This evolutionary link between sickle cell anemia and malaria can 
be interrogated in our model by looking at malarial infectivity differences between 
disease free and sickle cell patients.  
 
DARC AS A POTENTIAL MARKER FOR ERYTHROID MATURATION  
We know from looking at several time points in the differentiation protocol that 
these cells express an early, transient population of dual positive CD235 and DARC 
expressing cells. However the current hematopoietic protocol does not promote their 
expansion, and the population is lost despite prolonged time in differentiation and 
maturation media. Since DARC expression is found in later stage cells of the erythroid 
lineage, it is thought that DARC is a stage specific marker for more mature erythroid-
lineage cells. To increase DARC expression by cell maturation, the cell culture 
conditions were changed to favor expansion of these more mature cells. However, neither 
OP9 nor hypoxic growth conditions can promote the expansion of this transient 
population. 
Since DARC is a marker of mature erythrocytes, then the current differentiation 
and cell culture conditions do not favor maturation or sustain DARC expression, which is 
a limit to the current iPSC model. Little is known about the stage specific time point that 
DARC begins to be expressed in the erythroid lineage except that it is robustly expressed 
in reticulocytes (Woolley et al., 2005). Getting successful maturation of erythrocyte cells 
is possible but difficult in an in vitro setting. The resulting terminal mature erythrocytes 
are low in yield containing high levels of fetal hemoglobin and low levels of adult 
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hemoglobin—indicating a lack of switching that physiologically occurs in vivo 
(Lapillonne et al., 2010). 
The current protocol similarly shows high fetal hemoglobin content in the iPSC-
derived erythroid cells, which might be an indicator of fetal erythropoiesis instead of 
definitive erythropoiesis (Sturgeon et al., 2013). However, it is not known whether or not 
cells matured under the fetal-hematopoietic lineage pathway even express DARC, and 
that fetal infection by P.vivax might simply occur once definitive erythropoiesis is 
initiated a month into fetal development (Nosten et al., 1999; Palis et al,. 2010). 
Therefore, to create a more accurate iPSC based model, a focus on maturation of 
erythroid-lineage cells to the enucleated reticulocyte stage under definitive erythropoiesis 
would be the best way to move the model forward. 
In the absence of an iPSC-based model, it is possible to create an immortalized 
cell line of K562 kidney cells that express DARC through lentiviral infection 
(Tournamille et al., 2003). Guaranteed DARC expression in an immortalized cell line 
will allow for the continued use of the DBPII lentiviral vector as a way to continue 
modeling the mode of entry of P. vivax into DARC expressing cells. 
 
FUTURE APPLICATIONS 
The current model provides great potential for furthering malaria disease control 
by targeting the blood stage infection of the Plasmodium vivax human malaria parasite in 
DARC expressing reticulocytes. It creates a compelling platform for screening novel 
therapeutics—particularly those that block or inhibit the binding of the parasite to the 
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DARC receptor. Our model can be used to validate and measure efficacy of studies that 
have looked into antibody blocking of DARC and DBPII binding interactions (Shakri et 
al., 2012).  
While the current model focuses on modeling the erythrocyte stage of infection to 
help treat those infected with P. vivax malaria, future models should focus on the liver 
stage of infection. iPSC-derived hepatocytes can be used as a drug screen platform to 
eradicate hypnozoites as well as function as a liver toxin screen for novel therapeutics.  
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APPENDIX 
 
SUPPLEMENTAL FIGURES 
 
 
Supplemental Figure 1. Schematic of iPSC-based multisystem disease modeling of 
TTR Amyloidosis. iPSCs were created from peripheral blood samples taken from patients with 
familial amyloid polyneuropathy (FAP) or familial amyloid cardiomyopathy (FAC). 
Reprogramming was achieved with the STEMCCA lentiviral vector to create ATTR patient-
specific iPSCs, and these cells were directly differentiated into hepatocyte, neuronal, and 
cardiomyocyte lineages. Secreted supernatant from the iPSC-derived hepatocytes were used to 
dose the patient-matched neuron and cardiomyocyte- lineage cells. (Adapted from Leung et al., 
2013) 
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Supplemental Figure 2. Small molecules diflunisal and flufenamic acid can 
ameliorate the affects of aberrant ATTR proteins on iPSC-derived neuronal-lineage 
and cardiomyocyte cells. (A). Neuronal cells exposed to the hepatic supernatant (hs) derived 
from ATTRL55P iPSCs show increased cell death compared to neuronal cells exposed to disease-
free control hs as evidenced by dual staining with Hoecsht 33342 and propidium iodide analyzed 
by flow cytometry. The effects of the aberrant protein on the iPSC-derive neuronal-lineage cells 
is abrogated by a 6 day dose when exposed to one of the two protein-stabilizing compounds. (B) 
Cardiomyocytes also show increased cell death when exposed to ATTRL55P hs, Dual staining of 
Hoechst and propidium iodide show increased cell survivability after a 6 day dose of either one of 
the two small compounds. (Adpated from Leung et al., 2013) 
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